Compare IPCA Labs with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs JUBILANT LIFE SCIENCES - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS JUBILANT LIFE SCIENCES IPCA LABS/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 23.1 15.2 152.1% View Chart
P/BV x 4.5 1.8 252.6% View Chart
Dividend Yield % 0.1 0.8 12.5%  

Financials

 IPCA LABS   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    IPCA LABS
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
IPCA LABS/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs695898 77.4%   
Low Rs400618 64.8%   
Sales per share (Unadj.) Rs260.2572.0 45.5%  
Earnings per share (Unadj.) Rs19.036.2 52.4%  
Cash flow per share (Unadj.) Rs33.159.5 55.5%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.20.6 30.7%  
Book value per share (Unadj.) Rs213.0301.9 70.6%  
Shares outstanding (eoy) m126.20159.28 79.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.3 158.9%   
Avg P/E ratio x28.920.9 138.0%  
P/CF ratio (eoy) x16.612.7 130.1%  
Price / Book Value ratio x2.62.5 102.4%  
Dividend payout %5.312.4 42.4%   
Avg Mkt Cap Rs m69,120120,694 57.3%   
No. of employees `00013.32.4 554.6%   
Total wages/salary Rs m7,35919,260 38.2%   
Avg. sales/employee Rs Th2,477.438,120.6 6.5%   
Avg. wages/employee Rs Th555.28,058.4 6.9%   
Avg. net profit/employee Rs Th180.62,414.3 7.5%   
INCOME DATA
Net Sales Rs m32,83691,108 36.0%  
Other income Rs m418357 117.0%   
Total revenues Rs m33,25491,466 36.4%   
Gross profit Rs m4,50517,390 25.9%  
Depreciation Rs m1,7773,709 47.9%   
Interest Rs m2402,198 10.9%   
Profit before tax Rs m2,90511,840 24.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m5113,268 15.6%   
Profit after tax Rs m2,3945,770 41.5%  
Gross profit margin %13.719.1 71.9%  
Effective tax rate %17.627.6 63.7%   
Net profit margin %7.36.3 115.1%  
BALANCE SHEET DATA
Current assets Rs m19,45545,848 42.4%   
Current liabilities Rs m10,07620,897 48.2%   
Net working cap to sales %28.627.4 104.3%  
Current ratio x1.92.2 88.0%  
Inventory Days Days9857 172.4%  
Debtors Days Days6751 131.4%  
Net fixed assets Rs m20,26065,498 30.9%   
Share capital Rs m252159 158.4%   
"Free" reserves Rs m26,63347,930 55.6%   
Net worth Rs m26,88648,089 55.9%   
Long term debt Rs m2,34042,429 5.5%   
Total assets Rs m41,173114,685 35.9%  
Interest coverage x13.16.4 205.0%   
Debt to equity ratio x0.10.9 9.9%  
Sales to assets ratio x0.80.8 100.4%   
Return on assets %6.46.9 92.1%  
Return on equity %8.912.0 74.2%  
Return on capital %10.812.4 86.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64212,422 125.9%   
Fx outflow Rs m4,88417,227 28.3%   
Net fx Rs m10,759-4,805 -223.9%   
CASH FLOW
From Operations Rs m3,41111,215 30.4%  
From Investments Rs m-1,354-10,118 13.4%  
From Financial Activity Rs m-1,3046,574 -19.8%  
Net Cashflow Rs m7537,612 9.9%  

Share Holding

Indian Promoters % 45.9 45.6 100.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 11.4 8.7 131.0%  
FIIs % 25.3 21.2 119.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 21.1 82.5%  
Shareholders   36,892 23,815 154.9%  
Pledged promoter(s) holding % 2.1 15.9 13.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS